JAK inhibition with tofacitinib (JAK3>JAK1>JAK2), baricitinib (JAK1/2) or ruxolitinib (JAK1/2) showed efficacy for familial chilblain lupus in human case studies and small clinical trials (53, 169–171). This evidence concerns the gene JAK1 and familial chilblain lupus.